mRNA Therapeutics CDMO Global Market Insights: Growth Drivers, Size & Forecasts to 2029

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What Is the Forecasted Market Growth Rate of the mRNA Therapeutics CDMO Industry?
The market size for mRNA therapeutics CDMO has seen swift expansion over the past years. It's projected to rise from $4.24 billion in 2024 to $4.74 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.0%. The escalation in the historic period is due to factors such as the surging demand for quick vaccine development, amplified public and private investment in mRNA research, increasing occurrence of infectious diseases, broadening practices of pharmaceutical outsourcing, and a growing international emphasis on preparing for pandemics.

How Will the mRNA Therapeutics CDMO Market Size Evolve From 2025 to 2029?
In the coming years, a fast-paced expansion is projected for the mRNA therapeutics CDMO market, with an anticipated size of $7.40 billion by 2029 with a compound annual growth rate (CAGR) of 11.8%. Multiple factors contributing to this projected growth during the forecast period include an escalated interest in personalized medicine, an increased demand for quick response systems against new diseases, growing healthcare spending in emerging regions, expanded government support for local manufacturing, and surging interest towards non-infectious disease applications. Notable trends expected during the forecast period are the development of lipid nanoparticle delivery technologies, enhanced automation in manufacturing procedures, broader acceptance of modular and continuous manufacturing platforms, betterment of cold chain logistics infrastructure, and a rising implementation of artificial intelligence for process optimization.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-cdmo-global-market-report

What Are the Main Growth Drivers in the mRNA Therapeutics CDMO Market Today?
The escalating prevalence of chronic and infectious diseases is predicted to fuel the expansion of the mRNA therapeutics CDMO market. This includes persistent health issues such as diabetes, heart diseases, and asthma, as well as diseases brought on by harmful microorganisms, such as viruses, bacteria, and parasites, which can be directly or indirectly transmitted between individuals. The increase in such diseases can be attributed to aging populations, which are more prone to long-lasting illnesses and infections. mRNA therapeutics CDMO contributes to the combat against these diseases by offering comprehensive development and manufacturing services that speed up the provision of specific, personalized mRNA treatments to patients. For example, in April 2024, according to Allergy UK, a UK-based national charity, over 21 million people in the UK were affected by allergies, which had become the most frequently reported long-term health issue in 2022, with predictions suggesting that by 2026, half of Europe's population will suffer from at least one allergy. Therefore, the rising prevalence of chronic and infectious diseases is stimulating the expansion of the mRNA therapeutics CDMO market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25841&type=smp

Which mRNA Therapeutics CDMO Market Segment Is Expected to Lead Through 2029?
The mrna therapeutics cdmo market covered in this report is segmented -

1) By Type Of Service: Development Services, Manufacturing Services, Laboratory Services
2) By Indication: Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases
3) By Application: Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies
4) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations

Subsegments:
1) By Development Services: Process Development, Analytical Method Development, Formulation Development, Regulatory Support
2) By Manufacturing Services: Plasmid DNA Manufacturing, mRNA Synthesis, Lipid Nanoparticle (LNP) Formulation, Fill-Finish Services
3) By Laboratory Services: Quality Control Testing, Stability Testing, Bioanalytical Testing, Preclinical Testing

Which Market Trends Are Expected to Dominate mRNA Therapeutics CDMO Industry Growth?
Top businesses in the mRNA therapeutics CDMO market are making strides in developing innovative solutions, such as in situ nanomedicine vaccines. They aim to improve the precision and efficiency of mRNA-based vaccines through targeted immune stimulation. An in situ nanomedicine vaccine is an advanced mRNA-based therapy developed to generate nanomedicines within the patient's body. This allows for targeted delivery and personalized immune activation through engineered transgene expression. For example, in January 2025, Esphera SynBio Inc., a biotechnology company from Canada, announced a new initiative backed by the CQDM Quantum Leap program. The project is designed to evolve first-generation lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines with the inclusion of exclusive transgene designs. These designs trigger in vivo production of immunostimulatory nanomedicines, enabling precise antigen delivery and tailored immune responses. This positions the technology as a potential game-changer in vaccine technology innovation.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25841&type=smp

Which Companies Hold the Largest Market Share in the mRNA Therapeutics CDMO Sector?
Major companies operating in the mrna therapeutics cdmo market are Sanofi SA, Thermo Fisher Scientific Inc., Boehringer Ingelheim, Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, BioNTech SE, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Novo Holdings AS, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., CureVac SE, TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG, RiboPro

Where Is the mRNA Therapeutics CDMO Market Experiencing the Highest Growth?
North America was the largest region in the mRNA therapeutics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.